FDA Clears OrthoPediatrics' Pediatric PNP Retrograde Nail System
KIDS sits 77% above its 52-week low of $14.42.
Summary
OrthoPediatrics won FDA 510(k) clearance for its PNP Retrograde nail system, a device built specifically for pediatric bone anatomy with anatomic nails for trauma and straight nails for deformity. The PNP platform has already supported nearly 15,000 patients worldwide, so this clearance extends an existing franchise rather than launching an unproven product. The clearance landed alongside Q3 results: revenue of $72.7M versus $61.3M a year ago, with the loss per share narrowing to 25 cents from 50 cents. Management raised 2026 revenue guidance to $270M-$273M from $265M-$269M. Shares traded 7% higher after the bell at $25.49, near the 52-week high of $26.74, after closing the regular session at $23.82.
At the time of this announcement, KIDS was trading at $25.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $621.9M. The 52-week trading range was $14.42 to $26.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.